ECO 2026: Updates on Pharmacotherapy with Cagrilintide
Cagrilintide Does Not Affect the Exposure of the Combined Oral Contraceptive Ethinyloestradiol/Levonorgestrel or Gastric Emptying as Measured by the Paracetamol Absorption Test
Presenter :Van Der Horst, J.
This open‑label one-sequence crossover trial evaluated the effect of once‑weekly cagrilintide 4.5 mg on the pharmacokinetics of oral contraceptive (ethinyloestradiol [EE] 0.03 mg, levonorgestrel [LN] 0.15 mg) and gastric emptying in adult female participants of non-childbearing potential (n=30) with overweight/obesity (BMI 25-39.9 kg/m2).
EE exposure AUC0-24h was 1.10 (90% CI 0.94–1.28) and LN 0.92 (0.72–1.17); post-hoc sensitivity analysis showed EE 1.05 (1.00–1.10) and LN 1.01 (0.94–1.09). No differences were observed in Cmax or Tmax. Gastric emptying was unchanged (paracetamol AUC0–1h 1.10 95% CI [0.75–1.62]; AUC0–6h 1.18 [1.06–1.31]). All adverse events were non‑serious, mostly mild–moderate gastrointestinal, with 2 withdrawals.
Cagrilintide does not meaningfully affect contraceptive exposure or gastric emptying and demonstrates good tolerability.
33rd European Congress on Obesity (ECO 2026), 12th -15th May 2026, Istanbul, Turkey.
